57 citations
,
April 2009 in “Differentiation” This study demonstrates that SDF-1/CXCL12 and CXCR4 signaling play a crucial role in directing the migration and positioning of melanoblasts in mouse hair follicle formation.
32 citations
,
January 2024 in “The Journal of Experimental Medicine” This study found that CXCL12+ fibroblast subsets in mouse skin play a critical role in recruiting neutrophils and defending against S. aureus infection, with similar fibroblast activity observed in human psoriatic skin.
17 citations
,
January 2019 in “Annals of Dermatology” This study found that higher serum CXCL10 levels may predict the progression of non-segmental vitiligo, especially in patients also suffering from autoimmune thyroid disease and/or alopecia areata.
8 citations
,
January 2015 in “Genetics and Molecular Research” This study found that specific SNPs in the CXCL1 and CXCL2 genes may be associated with increased susceptibility to alopecia areata in the Korean population.
7 citations
,
October 2024 in “Frontiers in Immunology” In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.
6 citations
,
July 2021 in “Microbial biotechnology” This study found that combining LED yellow light with an engineered strain expressing CXCL12 improved wound healing and reduced inflammation in a mouse model of scald wounds.
4 citations
,
November 2021 in “Journal of Clinical Medicine” This study found no significant differences in certain proinflammatory protein levels between patients with alopecia areata and healthy controls but noted a potential association between disease severity and increased atherosclerosis risk.
3 citations
,
January 2016 in “Journal of Clinical & Cellular Immunology” In this study, increased production of CXCL10 was associated with the infiltration of Th1 and Tc1 cells in acute alopecia areata, suggesting a possible new target for treatment.
April 2026 in “Frontiers in Immunology” This study concluded that the CXCL12–CXCR4 signaling pathway significantly contributes to hair loss in androgenetic alopecia and alopecia areata by promoting inflammation and fibrosis, whereas inhibiting this pathway can restore hair growth and follicle health.
March 2026 in “Molecular and Cellular Biomedical Sciences” This study found that exosomes derived from hypoxia-conditioned mesenchymal stem cells modulated inflammatory biomarkers by decreasing CXCL12 and increasing IL-10 expression in a DHT-induced androgenic alopecia mouse model, indicating potential for treating hair loss through immunoregulation.
October 2025 in “Cell Reports” This study found that regulatory T cells accumulate in hair follicle epithelium via the Cxcr4-Cxcl12 axis, partially influenced by glucocorticoid receptor signaling, promoting hair regeneration; similar mechanisms were observed in human and murine skin.
July 2025 in “International Journal of Molecular Sciences” This study found that blocking the chemokine CXCL12 in a testosterone-induced mouse model of androgenetic alopecia restored hair regeneration and reduced fibrosis and immune alterations.
April 2025 in “ALEXMED ePosters” This study reported that CXCL12 may have a dual role in alopecia areata, where decreased levels could impair angiogenesis and disrupt vascular support to hair follicles, while its overexpression might exacerbate autoimmune attacks on hair follicles, contributing to hair loss.
December 2024 in “International Journal of Molecular Sciences” This study observed that CXCL12 is highly co-expressed with androgen receptors in human hair follicle cells, and its inhibition via antibodies increased hair length, suggesting a potential treatment strategy for androgenic alopecia.
January 2024 in “International Journal of Molecular Sciences” This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.
April 2022 in “Biomedicine & Pharmacotherapy” This study found that CXCL12 inhibits hair growth via the CXCR4/STAT signaling pathway, suggesting that targeting this pathway could be a promising approach for promoting hair growth.
June 2017 in “Experimental and Therapeutic Medicine” In a depilated mouse model, this study found that blocking CXCL4 activity with an anti-CXCL4 monoclonal antibody promoted hair growth by inducing an earlier anagen phase, delaying hair follicle regression, and altering expression of genes and proteins related to hair growth and cell proliferation.
September 2025 in “Genes” In this study, researchers reported that specific gene polymorphisms in Jiangnan cashmere goats, particularly SNPs in the HOXC13 and WNT4 genes, were significantly associated with key economic traits like birth weight and yearling weight, providing molecular markers for breeding and enhancing economic trait stability.
20 citations
,
December 2020 in “Frontiers in Immunology” This study found that certain T cell-associated genes were upregulated in dogs with Vogt-Koyanagi-Harada syndrome and vitiligo, suggesting a shared immunopathogenesis with humans.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.
71 citations
,
May 2024 in “New England Journal of Medicine” This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.
70 citations
,
April 2016 in “Experimental Dermatology” In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.
64 citations
,
July 2016 in “Journal of Immunology” In this study, blocking the CXCR3 receptor in mice prevented the development of alopecia areata by inhibiting the accumulation of specific T cells in the skin, suggesting a potential therapeutic approach for humans.
50 citations
,
March 2021 in “Annals of Translational Medicine” This study highlights the need for further research on dysregulated immune and fibrotic pathways in morphea to better understand its pathogenesis and develop new biomarkers and therapies.
48 citations
,
January 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” This study identified chemokine receptor ligands cxcl10 and cxcl11 as new hair-specific transcriptional targets of the Eda pathway, suggesting chemokine signaling plays a role in primary hair follicle patterning.
42 citations
,
December 2011 in “The journal of immunology/The Journal of immunology” In this study, transgenic mice with Rank expression in hair follicles showed excessive lymph node growth, which could be normalized by neutralizing the overproduced RANKL, underscoring its role in immune system regulation.
29 citations
,
April 2020 in “Journal of Tissue Engineering and Regenerative Medicine” This study demonstrates that incorporating human neopapilla into reconstructed human skin can initiate hair follicle morphogenesis by stimulating epidermal invagination and maintaining follicle-inductive properties in vitro.
23 citations
,
January 2017 in “Journal of Functional Biomaterials” This review examines the major biomaterials used in skin wound healing and evaluates experimental therapies but reports no new research findings.
22 citations
,
August 2009 in “Evidence-based Complementary and Alternative Medicine” This study found that a composition including Serenoa repens extract and anti-inflammatory agents effectively suppressed inflammation-related gene expression in a keratinocyte model, suggesting a potential dual strategy for treating androgenetic alopecia.
16 citations
,
September 2020 in “British journal of dermatology/British journal of dermatology, Supplement” This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.